Mortality and Morbidity of Heart Failure Hospitalization in Adult Patients With Congenital Heart Disease.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
05 Dec 2023
Historique:
medline: 7 12 2023
pubmed: 29 11 2023
entrez: 29 11 2023
Statut: ppublish

Résumé

Little is known about outcomes following heart failure (HF) hospitalization among adults with congenital heart disease (CHD) in the United States. We aim to compare the outcomes of HF versus non-HF hospitalizations in adults with CHD. Using a national deidentified administrative claims data set, patients with adult congenital heart disease (ACHD) hospitalized with and without HF (ACHDHF+, ACHDHF-) were characterized to determine the predictors of 90-day and 1-year mortality and quantify the risk of mortality, major adverse cardiac and cerebrovascular events, and health resource use. Cox proportional hazard regression was used to compare ACHDHF+ versus ACHDHF- for risk of events and health resource use. Of 26 454 unique ACHD admissions between January 1, 2010 and December 31, 2020, 5826 (22%) were ACHDHF+ and 20 628 (78%) were ACHDHF-. The ACHD HF+ hospitalizations increased from 6.6% to 14.0% ( HF hospitalization is associated with increased risk of mortality and morbidity with high health resource use in patients with ACHD. Recent cardiology clinic attendance appears to mitigate these risks.

Sections du résumé

BACKGROUND BACKGROUND
Little is known about outcomes following heart failure (HF) hospitalization among adults with congenital heart disease (CHD) in the United States. We aim to compare the outcomes of HF versus non-HF hospitalizations in adults with CHD.
METHODS AND RESULTS RESULTS
Using a national deidentified administrative claims data set, patients with adult congenital heart disease (ACHD) hospitalized with and without HF (ACHDHF+, ACHDHF-) were characterized to determine the predictors of 90-day and 1-year mortality and quantify the risk of mortality, major adverse cardiac and cerebrovascular events, and health resource use. Cox proportional hazard regression was used to compare ACHDHF+ versus ACHDHF- for risk of events and health resource use. Of 26 454 unique ACHD admissions between January 1, 2010 and December 31, 2020, 5826 (22%) were ACHDHF+ and 20 628 (78%) were ACHDHF-. The ACHD HF+ hospitalizations increased from 6.6% to 14.0% (
CONCLUSIONS CONCLUSIONS
HF hospitalization is associated with increased risk of mortality and morbidity with high health resource use in patients with ACHD. Recent cardiology clinic attendance appears to mitigate these risks.

Identifiants

pubmed: 38018491
doi: 10.1161/JAHA.123.030649
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e030649

Auteurs

Pradyumna Agasthi (P)

Department of Cardiovascular Medicine, Mayo Clinic Rochester MN USA.

Holly K Van Houten (HK)

Robert D. and Patricia E. Kern Center for the Science of Healthcare Delivery, Mayo Clinic Rochester MN USA.
OptumLabs Minnetonka MN USA.

Xiaoxi Yao (X)

Robert D. and Patricia E. Kern Center for the Science of Healthcare Delivery, Mayo Clinic Rochester MN USA.
OptumLabs Minnetonka MN USA.

C Charles Jain (CC)

Department of Cardiovascular Medicine, Mayo Clinic Rochester MN USA.

Alexander Egbe (A)

Department of Cardiovascular Medicine, Mayo Clinic Rochester MN USA.

Carole A Warnes (CA)

Department of Cardiovascular Medicine, Mayo Clinic Rochester MN USA.

William R Miranda (WR)

Department of Cardiovascular Medicine, Mayo Clinic Rochester MN USA.

Shannon M Dunlay (SM)

Department of Cardiovascular Medicine, Mayo Clinic Rochester MN USA.
Robert D. and Patricia E. Kern Center for the Science of Healthcare Delivery, Mayo Clinic Rochester MN USA.

Elizabeth H Stephens (EH)

Department of Cardiovascular Surgery, Mayo Clinic Rochester MN USA.

Jonathan N Johnson (JN)

Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine, Mayo Clinic Children's Center Rochester MN USA.

Heidi M Connolly (HM)

Department of Cardiovascular Medicine, Mayo Clinic Rochester MN USA.

Luke J Burchill (LJ)

Department of Cardiovascular Medicine, Mayo Clinic Rochester MN USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH